| Prev Close | 41.24 |
| Open | 41.59 |
| Day Low/High | 41.11 / 41.66 |
| 52 Wk Low/High | 31.43 / 48.25 |
| Volume | 2.18M |
| Avg Volume | 3.18M |
GlaxoSmithKline Plc (GSK)
41.20
0.04
0.10
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.51B |
| Market Cap | 102.02B |
| EPS | 2.40 |
| P/E Ratio | 23.73 |
| Div & Yield | 1.97 (4.86%) |
Latest News
GlaxoSmithKline Is Offering Subtle Clues for Investors
Let's check out the charts of this healthcare stock.
Jim Cramer: Are You a Star Player? Let's Put It to the Test
Do you know what a company does, does it do it well, and is there anything going on that could change the trajectory?
SPACs Aren't Just for Trading: 2 Attractive Buy and Hold Opportunities
I like putting some of my money with incredibly successful folks who are well-connected and have a history of success.
China Headline Risk, Valuation Station and a Workday Play
WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.
Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago
So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.
Sell Signals, 'Operation Warp Speed,' Trading Notes
Trump administration taps former GlaxoSmithKline exec as head of vaccine task force, and how I'm playing Walmart and Datadog.
Jim Cramer: Let the Froth Wash Out
Let's look at the stocks that will get crushed and that you can't touch right now.
Jim Cramer: Reopening Is Necessary, but Based on Little More Than Hope
It's imperative that people get back to work, so we have this great compromise -- let's see how it might play out.
GlaxoSmithKline Charts Prescribe Positive Outlook as It Chases Covid-19 Vaccine
The drugmaker that is partnering with Sanofi to develop a vaccine has seen its shares push higher after declining to a low in late March.
Jim Cramer: Don't Mistake the Rally for Cheering
There is no joy in stockville -- instead we have big companies with stocks rising. Here's why that is and what you need to understand about the rally amid the crisis.
Taking Stock of Recent Dividend Hikes
We've seen some high quarterly dividend increases of late, so let's pick out the crème of the crop.
GlaxoSmithKline: The Charts Are Pointing Higher
Our latest analysis and trading strategy for the the big pharma stock.
5 Best Buys for 2020 from Argus Research
Analysts from the independent research firm review their picks from last year and share their new favorites.
GlaxoSmithKline Could Trade Up to the $75 Area in the Months Ahead
Let's see what we might expect.
GlaxoSmithKline Could Rise 20% From Here
Shares of the pharma company have broken out on our Point and Figure chart.
Jim Cramer: Drug Stocks Are Too Cheap
These stocks are priced for total imperfection. That's just what you want.
GlaxoSmithKline Could Be Close to a Major Upside Move
The long-term technical view of GSK is very bullish.
China's Drugmakers Under Scrutiny After Stanford Admissions Scandal
Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?
Jim Cramer: How to Win Now, With or Without China
If we can advance without China then who the heck knows where we can go with it.
Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil
These themes are working despite the turmoil in Washington and slowing global growth.
Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative
So far 2019 is proving to be a year where things have a habit of working out right.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Get Ready to Buy the Big Upside Breakout on GlaxoSmithKline
Let's check out the charts.
Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
Celgene Deal Gets the M&A Ball Rolling in the New Year
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
This 2019 Market Optimism Is Misplaced: Market Recon
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
Pfizer Shares Jump on Monday After Company Signals Higher Price Push
Pfizer pushes higher on price increases.
Tech Selloff Could Work in Favor of Pharmaceutical Stocks
Pharma could be the best parking spot for your money if the market keeps trending downward.
